<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Subst Abuse</journal-id><journal-id journal-id-type="iso-abbrev">Subst Abuse</journal-id><journal-id journal-id-type="pmc-domain-id">1861</journal-id><journal-id journal-id-type="pmc-domain">sart</journal-id><journal-id journal-id-type="publisher-id">SAT</journal-id><journal-title-group><journal-title>Substance Abuse: Research and Treatment</journal-title></journal-title-group><issn pub-type="epub">1178-2218</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10034287</article-id><article-id pub-id-type="pmcid-ver">PMC10034287.1</article-id><article-id pub-id-type="pmcaid">10034287</article-id><article-id pub-id-type="pmcaiid">10034287</article-id><article-id pub-id-type="pmid">36968974</article-id><article-id pub-id-type="doi">10.1177/11782218231160014</article-id><article-id pub-id-type="publisher-id">10.1177_11782218231160014</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparing COVID-19-related Morbidity and Mortality Between Patients
With and Without Substance Use Disorders: A Retrospective Cohort
Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names initials="A">Angela</given-names></name><xref rid="aff1-11782218231160014" ref-type="aff">1</xref><xref rid="aff2-11782218231160014" ref-type="aff">2</xref><xref rid="fn1-11782218231160014" ref-type="author-notes">*</xref><xref rid="corresp1-11782218231160014" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burns</surname><given-names initials="R">Rebecca</given-names></name><xref rid="aff3-11782218231160014" ref-type="aff">3</xref><xref rid="fn1-11782218231160014" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ryan</surname><given-names initials="M">Morgan</given-names></name><xref rid="aff4-11782218231160014" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abbasi</surname><given-names initials="W">Wafaa</given-names></name><xref rid="aff5-11782218231160014" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harvey</surname><given-names initials="L">Leah</given-names></name><xref rid="aff1-11782218231160014" ref-type="aff">1</xref><xref rid="aff2-11782218231160014" ref-type="aff">2</xref><xref rid="aff6-11782218231160014" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hicks</surname><given-names initials="J">Jacqueline</given-names></name><xref rid="aff4-11782218231160014" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sinha</surname><given-names initials="P">Pranay</given-names></name><xref rid="aff1-11782218231160014" ref-type="aff">1</xref><xref rid="aff2-11782218231160014" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Assoumou</surname><given-names initials="SA">Sabrina A</given-names></name><xref rid="aff1-11782218231160014" ref-type="aff">1</xref><xref rid="aff2-11782218231160014" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1-11782218231160014"><label>1</label>Section of Infectious Diseases,
Department of Medicine, Boston Medical Center, Boston, MA, USA</aff><aff id="aff2-11782218231160014"><label>2</label>Section of Infectious Diseases,
Department of Medicine, Boston University School of Medicine, Boston, MA, USA</aff><aff id="aff3-11782218231160014"><label>3</label>Internal Medicine Residency Program,
Department of Medicine, Boston University School of Medicine, Boston, MA, USA</aff><aff id="aff4-11782218231160014"><label>4</label>Department of Biostatistics, Boston
University School of Public Health, Boston, MA, USA</aff><aff id="aff5-11782218231160014"><label>5</label>Boston University School of Medicine,
Boston, MA, USA</aff><aff id="aff6-11782218231160014"><label>6</label>Grayken Center for Addiction,
Department of Medicine, Boston University School of Medicine, Boston, MA, USA</aff><author-notes><corresp id="corresp1-11782218231160014">Angela McLaughlin, Section of Infectious
Diseases, Boston Medical Center, 801 Massachusetts Avenue, Crosstown Center, 2nd
Floor, Boston, MA 02118, USA. Email:
<email>Angela.Mclaughlin@bmc.org</email></corresp><corresp id="corresp2-11782218231160014">Sabrina A Assoumou, Section of Infectious
Diseases, Boston Medical Center, 801 Massachusetts Avenue, Crosstown Center, 2nd
Floor, Boston, MA 02118, USA. Email:
<email>Sabrina.Assoumou@bmc.org</email></corresp><fn fn-type="equal" id="fn1-11782218231160014"><label>*</label><p>Contributed equally to this project.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">425274</issue-id><elocation-id>11782218231160014</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>9</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-14 03:25:39.963"><day>14</day><month>09</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10034287</article-id><article-id pub-id-type="doi">10.1177/11782218231160014</article-id><article-version>1</article-version><pub-date><day>22</day><month>03</month><year>2023</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10037129</article-id><article-id pub-id-type="doi">10.1177/11782218231160014</article-id><article-version>2</article-version><pub-date><day>22</day><month>03</month><year>2023</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_11782218231160014.pdf"/><abstract><sec id="section1-11782218231160014"><title>Objectives:</title><p>People with substance use disorders (SUD) are suggested to have higher risk
of hospitalization, intubation, or death from coronavirus disease 2019
(COVID-19), although data are mixed. Little is known about other
COVID-19-related complications in this group. We compared morbidity and
mortality among individuals with and without SUD who were admitted to an
urban safety net hospital with COVID-19 early in the pandemic,
contemporaneous to other published studies on this subject.</p></sec><sec id="section2-11782218231160014"><title>Methods:</title><p>We performed a retrospective study of patients &#10878;18&#8201;years old admitted with
COVID-19 from March 16th to April 8th, 2020. SUD included alcohol, opioid,
cocaine, amphetamine, and benzodiazepine use disorders and was identified
using diagnostic codes, free text clinical documentation, and urine drug
screens. The primary outcome was inpatient mortality. Secondary outcomes
included clinical complications (eg, secondary infections, venous
thromboembolism) and resource utilization (eg, mechanical ventilation,
length of stay). We used multivariable regression to assess the relationship
between SUD and mortality.</p></sec><sec id="section3-11782218231160014"><title>Results:</title><p>Of 409 patients, the mean age was 56&#8201;years and 13.7% had SUD. Those with SUD
were more likely to be male, have experienced homelessness, have pulmonary
disease or hepatitis C, or use tobacco or cannabis. After multivariable
analysis, SUD was not associated with mortality (aOR 1.03; 95% CI,
0.31-3.10). Secondary outcomes were also similar between groups.</p></sec><sec id="section4-11782218231160014"><title>Conclusions:</title><p>Our findings suggest that persons with and without SUD have similar
COVID-19-related outcomes. Previously reported increased COVID-19
complications may be from medical comorbidities.</p></sec></abstract><kwd-group><kwd>COVID-19</kwd><kwd>substance use</kwd><kwd>addiction</kwd><kwd>safety net</kwd><kwd>complications</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-11782218231160014"><funding-source id="funding1-11782218231160014"><institution-wrap><institution>National Institute of Allergy and Infectious
Diseases</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000060</institution-id></institution-wrap></funding-source><award-id rid="funding1-11782218231160014">T32AI052074 to A.M., L.H., and
P.S.</award-id></award-group><award-group id="award2-11782218231160014"><funding-source id="funding2-11782218231160014"><institution-wrap><institution>Boston University</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007161</institution-id></institution-wrap></funding-source><award-id rid="funding2-11782218231160014">School of Medicine Department of
Medicine Evans Ca</award-id></award-group><award-group id="award3-11782218231160014"><funding-source id="funding3-11782218231160014"><institution-wrap><institution>National Institute on Drug Abuse</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000026</institution-id></institution-wrap></funding-source><award-id rid="funding3-11782218231160014">K23DA044085 to S.A.A.</award-id></award-group><award-group id="award4-11782218231160014"><funding-source id="funding4-11782218231160014"><institution-wrap><institution>National Institute on Drug Abuse</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000026</institution-id></institution-wrap></funding-source><award-id rid="funding4-11782218231160014">R25DA033211 to L.H</award-id></award-group><award-group id="award5-11782218231160014"><funding-source id="funding5-11782218231160014"><institution-wrap><institution>Burroughs Wellcome Fund</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000861</institution-id></institution-wrap></funding-source><award-id rid="funding5-11782218231160014">Postdoctoral fellowship to
P.S.</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2023</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-11782218231160014"><title>Introduction</title><p>The coronavirus disease 2019 (COVID-19) pandemic has highlighted the unique health
disparities that have long impacted people who use drugs.<sup><xref rid="bibr1-11782218231160014" ref-type="bibr">1</xref>,<xref rid="bibr2-11782218231160014" ref-type="bibr">2</xref></sup> Persons with substance use
disorders (SUD) experience numerous barriers to care, such as difficulty engaging
with traditional care models, financial insecurity, unstable housing, and social
stigmas.<sup><xref rid="bibr3-11782218231160014" ref-type="bibr">3</xref>,<xref rid="bibr4-11782218231160014" ref-type="bibr">4</xref></sup>
These barriers were further compounded by the association between lockdowns and
increased substance use, especially in those with a preexisting history of
SUD.<sup><xref rid="bibr5-11782218231160014" ref-type="bibr">5</xref>,<xref rid="bibr6-11782218231160014" ref-type="bibr">6</xref></sup></p><p>Multiple large cohort studies from early in the pandemic have shown higher rates of
hospitalization, intubation, and death from COVID-19 in those with SUD.<sup><xref rid="bibr7-11782218231160014" ref-type="bibr">7</xref><xref rid="bibr8-11782218231160014" ref-type="bibr"/><xref rid="bibr9-11782218231160014" ref-type="bibr"/>-<xref rid="bibr10-11782218231160014" ref-type="bibr">10</xref></sup> Alternatively, 2 large
studies from the Veterans Health Administration found no associations between SUD
and COVID-19-related mortality,<sup><xref rid="bibr11-11782218231160014" ref-type="bibr">11</xref>,<xref rid="bibr12-11782218231160014" ref-type="bibr">12</xref></sup> and another cohort of 5107
people with SUD showed mixed results depending on substance use pattern.<sup><xref rid="bibr13-11782218231160014" ref-type="bibr">13</xref></sup> Given these
conflicting data, the Centers for Disease Control and Prevention has classified
persons with SUD as suggestive of higher risk for severe COVID-19.<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup></p><p>Moreover, little is known about the incidence of other COVID-associated clinical
complications (eg, venous thromboembolism, bacterial superinfections, renal failure
requiring dialysis) among persons with SUD, nor of the relationship between SUD and
COVID-19-related resource utilization (eg, duration of hospitalization and intensive
care unit [ICU] stay). Such factors could influence how clinicians anticipate the
healthcare needs and likelihood of clinical decompensation of people with SUD.</p><p>It is critical to better understand how SUD impacts COVID-19 disease severity. Safety
net hospitals like Boston Medical Center (BMC) treat patients regardless of ability
to pay and therefore primarily serve under-resourced communities. They also treat a
large proportion of patients with SUD and offer unique insights into the effects of
the COVID-19 pandemic on these individuals.</p><p>The goal of the current study is to assess the association between SUD and inpatient
COVID-19-related mortality, as data published thus far have been mixed.
Additionally, we examined the clinical complications and healthcare utilization of
hospitalized patients with COVID-19 and SUD as compared to those without SUD. Using
clinical records from BMC, we built on prior studies by providing more granularity
regarding COVID-19 presentation, such as clinical severity on admission as estimated
by oxygenation status, as well as COVID-19-related complications. Given that prior
studies have been limited by the reduced sensitivity of diagnostic codes to identify
SUD,<sup><xref rid="bibr7-11782218231160014" ref-type="bibr">7</xref><xref rid="bibr8-11782218231160014" ref-type="bibr"/><xref rid="bibr9-11782218231160014" ref-type="bibr"/><xref rid="bibr10-11782218231160014" ref-type="bibr"/><xref rid="bibr11-11782218231160014" ref-type="bibr"/>-<xref rid="bibr12-11782218231160014" ref-type="bibr">12</xref>,<xref rid="bibr15-11782218231160014" ref-type="bibr">15</xref>,<xref rid="bibr16-11782218231160014" ref-type="bibr">16</xref></sup> we conducted more detailed
manual data abstraction to better identify patients with SUD. We used a cohort
contemporaneous to prior studies that had been done early in the pandemic, which
allows our findings to be interpreted in the same context as the Centers for Disease
Control and Prevention risk stratification.</p></sec><sec sec-type="materials|methods" id="section6-11782218231160014"><title>Materials and Methods</title><sec id="section7-11782218231160014"><title>Setting, study population, and inclusion criteria</title><p>We created a retrospective cohort of patients with COVID-19 admitted to BMC
during the first month of the initial surge in Massachusetts. With approximately
500 beds, BMC is the largest safety net hospital in New England and provides
care to a racially and ethnically diverse and low-income patient
population.<sup><xref rid="bibr17-11782218231160014" ref-type="bibr">17</xref></sup> Moreover, BMC serves a large proportion of patients
with SUD and associated morbidities, such as hepatitis C virus (HCV) and human
immunodeficiency virus (HIV).<sup><xref rid="bibr18-11782218231160014" ref-type="bibr">18</xref>,<xref rid="bibr19-11782218231160014" ref-type="bibr">19</xref></sup> In addition, BMC provides
care to communities in Boston with the highest COVID-19 disease burden,
including low-income areas and locations with predominantly Black and Latino
individuals.<sup><xref rid="bibr20-11782218231160014" ref-type="bibr">20</xref></sup></p><p>We included patients at least 18&#8201;years old and admitted between March 16th, 2020,
and April 8th, 2020, for symptoms consistent with COVID-19 with a positive
reverse-transcriptase polymerase chain reaction test (nasopharyngeal or tracheal
aspirate) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We
excluded patients who contracted COVID-19 during their hospital stay or who were
admitted for reasons unrelated to COVID-19 and then were incidentally found to
be SARS-CoV-2 positive. March 16th was the admission date of the first COVID-19
patient with positive nucleic acid testing at BMC. April 8th was used as an end
date due to revision of BMC&#8217;s COVID-19 treatment protocol.</p></sec><sec id="section8-11782218231160014"><title>Data collection</title><p>We manually abstracted data on demographics, medical comorbidities, substance use
histories, symptoms, and clinical course from the electronic medical record
using International Classification of Disease, 10th Revision (ICD-10) codes and
clinician documentation. We followed patients until discharge, transfer to
another facility, or death.</p><p>We estimated baseline clinical severity by oxygenation status on admission. As
routine blood gases were not collected on admission, we calculated oxygenation
as the ratio of peripheral capillary oxygen saturation to fraction of inspired
oxygen (SpO<sub>2</sub>/FiO<sub>2</sub>), which prior literature has established
to approximate partial pressure of oxygen (PaO<sub>2</sub>) to FiO<sub>2</sub>
ratios.<sup><xref rid="bibr21-11782218231160014" ref-type="bibr">21</xref></sup> FiO<sub>2</sub> was estimated based on the EPIC II
Study &#8220;Estimating FiO<sub>2</sub>&#8221; table for patients who were not mechanically
ventilated or managed on non-invasive positive pressure ventilation.<sup><xref rid="bibr22-11782218231160014" ref-type="bibr">22</xref></sup> The
Boston University Medical Center Institutional Review Board approved this
study.</p></sec><sec id="section9-11782218231160014"><title>Exposures</title><p>Evidence of lifetime SUD was the exposure of interest and was obtained via review
of ICD-10 diagnosis codes listed on patient problem lists at the time of
COVID-19 diagnosis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/11782218231160014" ext-link-type="uri">Supplemental Table 1</ext-link>). To increase the sensitivity of SUD
identification, we additionally reviewed free text clinical documentation and
urine drug screen to assess for SUD or heavy substance use suggestive of SUD
that was not documented by ICD-10 codes. For these additional reviews, we
included current or past alcohol intake consistent with heavy alcohol use or
alcohol use disorder as defined by the National Institute on Alcohol Abuse and
Alcoholism<sup><xref rid="bibr23-11782218231160014" ref-type="bibr">23</xref></sup>; cocaine use; or non-prescription opioid,
benzodiazepine, or amphetamine use. Prescribed opioid, benzodiazepine, and
amphetamine use was classified as SUD if there was documentation of concern for
a use disorder in the electronic medical record. We did not include cannabis use
disorder in our definition of SUD because of substantial under-detection of
cannabis use disorder by ICD-10 codes<sup><xref rid="bibr24-11782218231160014" ref-type="bibr">24</xref><xref rid="bibr25-11782218231160014" ref-type="bibr"/>-<xref rid="bibr26-11782218231160014" ref-type="bibr">26</xref></sup> and inconsistent language
describing cannabis consumption which limits identification of use disorders
with free text documentation.<sup><xref rid="bibr26-11782218231160014" ref-type="bibr">26</xref>,<xref rid="bibr27-11782218231160014" ref-type="bibr">27</xref></sup> We also did not include
other substances such as inhalants and hallucinogens as they were rarely
reported in the charts.</p><p>Use of immunomodulatory agents as COVID-19 directed therapy was the secondary
exposure. During the spring of 2020, data were limited on COVID-19 treatment
options. BMC developed a standardized and closely monitored protocol for
administering off-label immunomodulatory therapy to decompensating patients
based on degree of hypoxemia and changes in blood inflammatory markers.
Clinicians used either interleukin-6 receptor inhibitors (IL-6 receptor
inhibitors; tocilizumab or sarilumab) or an interleukin-1 receptor inhibitor
(IL-1 receptor inhibitor; anakinra).<sup><xref rid="bibr28-11782218231160014" ref-type="bibr">28</xref></sup> IL-6 receptor inhibitors
have since been added to national treatment guidelines for patients with severe
progressive COVID-19 disease after multiple observational studies and clinical
trials.<sup><xref rid="bibr29-11782218231160014" ref-type="bibr">29</xref></sup> Most patients with COVID-19 were also prescribed
hydroxychloroquine and azithromycin, although these were removed from the
protocol in April 2020 shortly after the period we are evaluating, as newer
studies pointed away from their efficacy. Details of the BMC treatment algorithm
are discussed more extensively in a prior study.<sup><xref rid="bibr28-11782218231160014" ref-type="bibr">28</xref></sup></p></sec><sec id="section10-11782218231160014"><title>Primary and secondary outcomes</title><p>Our primary outcome was inpatient mortality in patients with COVID-19. Secondary
outcomes included inpatient clinical complications (secondary bacterial
infections, renal failure requiring dialysis, venous thromboembolism, stroke,
hepatitis, myocardial infarct, multisystem organ failure, and a composite
outcome &#8220;any complication&#8221; including the presence of at least one of any of the
clinical complications) and resource utilization (mechanical ventilation, ICU
admission, hospital and ICU length of stay, and time to ICU admission and
intubation). These outcomes were identified by manual chart abstraction. In
addition, we evaluated factors associated with IL-6 receptor inhibitor
administration given BMC&#8217;s frequent use of these medications that may have
influenced likelihood of clinical complications.</p></sec><sec id="section11-11782218231160014"><title>Statistical analysis</title><p>We reported categorical variables as counts and percentages and continuous
variables as means and standard deviations for variables that followed a normal
distribution. Median and interquartile ranges were reported for continuous
variables that did not follow a normal distribution. We evaluated differences
between patients with and without SUD using chi-squared tests for categorical
variables, Fisher&#8217;s exact test for categorical variables with small counts,
2-sided <italic toggle="yes">t</italic>-tests for continuous variables, and 2-sided Wilcoxon
rank sum tests for continuous variables that were non-normal. We included in the
multivariable models clinical and demographic variables associated with severe
COVID-19<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup> as well as variables significant at the .2 level in the
bivariate analysis. We dichotomized race into non-White and White for the
multivariable models given our sample size and because other studies have shown
associations of non-White race with poorer COVID-19 outcomes.<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup>
Associations from multivariable analyses were expressed by odds ratio (OR) with
corresponding confidence intervals and p-values with significance defined at the
0.05 level. Analyses were conducted with R v4.0.3 (R Core Team, 2020).<sup><xref rid="bibr30-11782218231160014" ref-type="bibr">30</xref></sup></p></sec></sec><sec sec-type="results" id="section12-11782218231160014"><title>Results</title><sec id="section13-11782218231160014"><title>Cohort characteristics</title><p>A total of 409 patients were included in the cohort (<xref rid="fig1-11782218231160014" ref-type="fig">Figure 1</xref>) and 56 (13.7%) met criteria
for SUD. Baseline characteristics of the study population are presented in <xref rid="table1-11782218231160014" ref-type="table">Table 1</xref>. Mean age and
racial/ethnic backgrounds of the SUD and non-SUD groups were similar. Patients
with SUD were more likely to be male (83.9% vs 52.1%), experience homelessness
(33.9% vs 4.8%), have chronic pulmonary disease (23.2% vs 5.7%), and have a
positive HCV antibody (23.2% vs 1.7%). The most commonly used substances were
alcohol (71.4%), cocaine (39.3%), and opioids (32.1%). People with SUD were also
more likely to use tobacco (67.9% vs 24.9%) and cannabis (16.1% vs 4.0%).
Patients in the SUD group presented to care 2&#8201;days earlier after symptom onset
than people in the non-SUD group (4.0 vs 6.0&#8201;days,
<italic toggle="yes">P</italic>&#8201;=&#8201;&lt;&#8201;.001) (<xref rid="table2-11782218231160014" ref-type="table">Table 2</xref>). Patients without SUD were
more likely to present with fever, cough, or diarrhea, but otherwise presenting
symptoms were similar (<xref rid="table2-11782218231160014" ref-type="table">Table 2</xref>). Both groups presented with similar baseline oxygenation as
measured by SpO<sub>2</sub>/FiO<sub>2</sub> (<xref rid="table2-11782218231160014" ref-type="table">Table 2</xref>).</p><fig position="float" id="fig1-11782218231160014" orientation="portrait"><label>Figure 1.</label><caption><p>Study flow.</p><p>Abbreviations: COVID-19, coronavirus disease 2019; RT-PCR, reverse
transcription polymerase chain reaction; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-fig1.jpg"/></fig><table-wrap position="float" id="table1-11782218231160014" orientation="portrait"><label>Table 1.</label><caption><p>Characteristics of patients by substance use disorder (SUD) status.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Non-SUD</th><th align="left" rowspan="1" colspan="1">SUD</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<sup><xref rid="table-fn1-11782218231160014" ref-type="table-fn">*</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total (%); n&#8201;=&#8201;409</td><td rowspan="1" colspan="1">353 (86.3)</td><td rowspan="1" colspan="1">56 (13.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean age (sd)</td><td rowspan="1" colspan="1">55.9 (16.7)</td><td rowspan="1" colspan="1">56.5 (13.4)</td><td rowspan="1" colspan="1">.804</td></tr><tr><td rowspan="1" colspan="1">Male (%)</td><td rowspan="1" colspan="1">184 (52.1)</td><td rowspan="1" colspan="1">47 (83.9)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">Race/Ethnicity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.341</td></tr><tr><td rowspan="1" colspan="1">&#8195;Asian (%)</td><td rowspan="1" colspan="1">6 (1.7)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Black or African American (%)</td><td rowspan="1" colspan="1">166 (47.0)</td><td rowspan="1" colspan="1">28 (50.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;White (%)</td><td rowspan="1" colspan="1">41 (11.6)</td><td rowspan="1" colspan="1">11 (19.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Hispanic or Latino (%)</td><td rowspan="1" colspan="1">77 (21.8)</td><td rowspan="1" colspan="1">11 (19.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown (%)</td><td rowspan="1" colspan="1">63 (17.8)</td><td rowspan="1" colspan="1">6 (10.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Experiencing homelessness (%)</td><td rowspan="1" colspan="1">17 (4.8)</td><td rowspan="1" colspan="1">19 (33.9)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td colspan="4" rowspan="1">
<italic toggle="yes">Comorbid illness</italic>
</td></tr><tr><td rowspan="1" colspan="1">Hypertension (%)</td><td rowspan="1" colspan="1">222 (62.9)</td><td rowspan="1" colspan="1">28 (50.0)</td><td rowspan="1" colspan="1">.091</td></tr><tr><td rowspan="1" colspan="1">Cardiac disease<sup><xref rid="table-fn2-11782218231160014" ref-type="table-fn">a</xref></sup>
(%)</td><td rowspan="1" colspan="1">70 (19.8)</td><td rowspan="1" colspan="1">16 (28.6)</td><td rowspan="1" colspan="1">.189</td></tr><tr><td rowspan="1" colspan="1">Diabetes (%)</td><td rowspan="1" colspan="1">152 (43.1)</td><td rowspan="1" colspan="1">18 (32.1)</td><td rowspan="1" colspan="1">.163</td></tr><tr><td rowspan="1" colspan="1">Obesity<sup><xref rid="table-fn3-11782218231160014" ref-type="table-fn">b</xref></sup>
(%)</td><td rowspan="1" colspan="1">190 (53.8)</td><td rowspan="1" colspan="1">23 (41.1)</td><td rowspan="1" colspan="1">.150</td></tr><tr><td rowspan="1" colspan="1">Obstructive sleep apnea (%)</td><td rowspan="1" colspan="1">38 (10.8)</td><td rowspan="1" colspan="1">6 (10.7)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Chronic pulmonary disease<sup><xref rid="table-fn4-11782218231160014" ref-type="table-fn">c</xref></sup>
(%)</td><td rowspan="1" colspan="1">20 (5.7)</td><td rowspan="1" colspan="1">13 (23.2)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease<sup><xref rid="table-fn5-11782218231160014" ref-type="table-fn">d</xref></sup></td><td rowspan="1" colspan="1">60 (17.0)</td><td rowspan="1" colspan="1">11 (19.6)</td><td rowspan="1" colspan="1">.767</td></tr><tr><td rowspan="1" colspan="1">Asthma (%)</td><td rowspan="1" colspan="1">47 (13.3)</td><td rowspan="1" colspan="1">7 (12.5)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Cirrhosis (%)</td><td rowspan="1" colspan="1">4 (1.1)</td><td rowspan="1" colspan="1">2 (3.6)</td><td rowspan="1" colspan="1">.192</td></tr><tr><td rowspan="1" colspan="1">HIV<sup><xref rid="table-fn6-11782218231160014" ref-type="table-fn">e</xref></sup>
(%)</td><td rowspan="1" colspan="1">13 (3.7)</td><td rowspan="1" colspan="1">3 (5.4)</td><td rowspan="1" colspan="1">.469</td></tr><tr><td rowspan="1" colspan="1">HBV sAg<sup><xref rid="table-fn7-11782218231160014" ref-type="table-fn">f</xref></sup>
positive (%)</td><td rowspan="1" colspan="1">5 (1.4)</td><td rowspan="1" colspan="1">2 (3.6)</td><td rowspan="1" colspan="1">.247</td></tr><tr><td rowspan="1" colspan="1">HCV Ab<sup><xref rid="table-fn8-11782218231160014" ref-type="table-fn">g</xref></sup>
positive (%)</td><td rowspan="1" colspan="1">6 (1.7)</td><td rowspan="1" colspan="1">13 (23.2)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td colspan="4" rowspan="1">
<italic toggle="yes">Substance use</italic>
</td></tr><tr><td rowspan="1" colspan="1">Opioids (%)</td><td rowspan="1" colspan="1">--</td><td rowspan="1" colspan="1">18 (32.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alcohol<sup><xref rid="table-fn9-11782218231160014" ref-type="table-fn">h</xref></sup>
(%)</td><td rowspan="1" colspan="1">--</td><td rowspan="1" colspan="1">40 (71.4)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cocaine (%)</td><td rowspan="1" colspan="1">--</td><td rowspan="1" colspan="1">22 (39.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Other SU (%)</td><td rowspan="1" colspan="1">--</td><td rowspan="1" colspan="1">2 (3.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Any tobacco use</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;No (%)</td><td rowspan="1" colspan="1">252 (71.4)</td><td rowspan="1" colspan="1">18 (32.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes (%)</td><td rowspan="1" colspan="1">88 (24.9)</td><td rowspan="1" colspan="1">38 (67.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown (%)</td><td rowspan="1" colspan="1">13 (3.7)</td><td rowspan="1" colspan="1">--</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Marijuana use (%)</td><td rowspan="1" colspan="1">14 (4.0)</td><td rowspan="1" colspan="1">9 (16.1)</td><td rowspan="1" colspan="1">.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-11782218231160014"><label>*</label><p>Chi-squared tests for categorical variables, Fisher&#8217;s exact test for
categorical variables with small cell counts,
<italic toggle="yes">t</italic>-tests for continuous variables, and Wilcoxon
rank-sum test for non-normal continuous variables.</p></fn><fn id="table-fn2-11782218231160014"><label>a</label><p>Coronary artery disease, congenital heart disease, or heart
failure.</p></fn><fn id="table-fn3-11782218231160014"><label>b</label><p>Body mass index &#10878;30&#8201;kg/m&#178;</p></fn><fn id="table-fn4-11782218231160014"><label>c</label><p>Chronic obstructive pulmonary disease or restrictive lung
disease.</p></fn><fn id="table-fn5-11782218231160014"><label>d</label><p>Chronic kidney disease stage 3 or higher, or on dialysis.</p></fn><fn id="table-fn6-11782218231160014"><label>e</label><p>Human immunodeficiency virus.</p></fn><fn id="table-fn7-11782218231160014"><label>f</label><p>Hepatitis B virus surface antigen.</p></fn><fn id="table-fn8-11782218231160014"><label>g</label><p>Hepatitis C virus antibody.</p></fn><fn id="table-fn9-11782218231160014"><label>h</label><p>Heavy alcohol use or alcohol use disorder as defined by the National
Institute on Alcohol Abuse and Alcoholism.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table2-11782218231160014" orientation="portrait"><label>Table 2.</label><caption><p>Symptoms and oxygenation at presentation by substance use disorder (SUD)
Status.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Non-SUD</th><th align="left" rowspan="1" colspan="1">SUD</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<sup><xref rid="table-fn10-11782218231160014" ref-type="table-fn">*</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total (n&#8201;=&#8201;409)</td><td rowspan="1" colspan="1">353 (86.3)</td><td rowspan="1" colspan="1">56 (13.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Symptom duration (median days (IQR))</td><td rowspan="1" colspan="1">6.0 (6.0)</td><td rowspan="1" colspan="1">4.0 (6.0)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">Fever (%)</td><td rowspan="1" colspan="1">270 (76.5)</td><td rowspan="1" colspan="1">35 (62.5)</td><td rowspan="1" colspan="1">.039</td></tr><tr><td rowspan="1" colspan="1">Cough (%)</td><td rowspan="1" colspan="1">278 (78.8)</td><td rowspan="1" colspan="1">36 (64.3)</td><td rowspan="1" colspan="1">.027</td></tr><tr><td rowspan="1" colspan="1">Dyspnea (%)</td><td rowspan="1" colspan="1">230 (65.2)</td><td rowspan="1" colspan="1">34 (60.7)</td><td rowspan="1" colspan="1">.620</td></tr><tr><td rowspan="1" colspan="1">Myalgias (%)</td><td rowspan="1" colspan="1">158 (44.8)</td><td rowspan="1" colspan="1">22 (39.3)</td><td rowspan="1" colspan="1">.534</td></tr><tr><td rowspan="1" colspan="1">Diarrhea (%)</td><td rowspan="1" colspan="1">100 (28.3)</td><td rowspan="1" colspan="1">8 (14.3)</td><td rowspan="1" colspan="1">.040</td></tr><tr><td rowspan="1" colspan="1">Anosmia (%)</td><td rowspan="1" colspan="1">24 (6.8)</td><td rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1">.227</td></tr><tr><td rowspan="1" colspan="1">Headache (%)</td><td rowspan="1" colspan="1">96 (27.2)</td><td rowspan="1" colspan="1">10 (17.9)</td><td rowspan="1" colspan="1">.188</td></tr><tr><td rowspan="1" colspan="1">SpO<sub>2</sub>/FiO<sub>2</sub><sup><xref rid="table-fn11-11782218231160014" ref-type="table-fn">a</xref></sup>
(mean (SD))</td><td rowspan="1" colspan="1">422.0 (86.0)</td><td rowspan="1" colspan="1">424.7 (82.7)</td><td rowspan="1" colspan="1">.828</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn10-11782218231160014"><label>*</label><p>Chi-squared tests for categorical variables, Fisher&#8217;s exact test for
categorical variables with small cell counts, t-tests for continuous
variables, and Wilcoxon rank-sum test for non-normal continuous
variables.</p></fn><fn id="table-fn11-11782218231160014"><label>a</label><p>Ratio of peripheral capillary oxygen saturation to fraction of
inspired oxygen, to measure oxygenation on hospital admission.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section14-11782218231160014"><title>Outcomes</title><p>In the SUD group, 7 people (12.5%) died while admitted for COVID-19 infection, as
compared to 30 (8.5%) in the non-SUD group (<xref rid="table3-11782218231160014" ref-type="table">Table 3</xref>). We did not find an
association between SUD and our primary outcome of inpatient mortality (aOR
1.03; 95% CI, 0.31-3.10) after multivariable analysis controlling for age, sex,
non-White race, baseline oxygenation by SpO<sub>2</sub>/FiO<sub>2</sub>,
administration of IL-6 receptor inhibitor therapy, cardiac disease, and tobacco
use (<xref rid="table4-11782218231160014" ref-type="table">Table 4</xref>).
Factors significantly associated with mortality included age (aOR 1.04;
1.01-1.08), baseline oxygenation by SpO<sub>2</sub>/FiO<sub>2</sub> (aOR 0.58;
0.41-0.84), and presence of cardiac disease (aOR 2.55; 1.00-6.54).</p><table-wrap position="float" id="table3-11782218231160014" orientation="portrait"><label>Table 3.</label><caption><p>Patient outcomes by substance use disorder (SUD) Status.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Non-SUD</th><th align="left" rowspan="1" colspan="1">SUD</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<sup><xref rid="table-fn12-11782218231160014" ref-type="table-fn">*</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total (n&#8201;=&#8201;409)</td><td rowspan="1" colspan="1">353 (86.3)</td><td rowspan="1" colspan="1">56 (13.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alive at discharge (%)</td><td rowspan="1" colspan="1">323 (91.5)</td><td rowspan="1" colspan="1">49 (87.5)</td><td rowspan="1" colspan="1">.472</td></tr><tr><td rowspan="1" colspan="1">Death during study period (%)</td><td rowspan="1" colspan="1">30 (8.5)</td><td rowspan="1" colspan="1">7 (12.5)</td><td rowspan="1" colspan="1">.472</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">COVID-19 directed therapies</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Azithromycin (%)</td><td rowspan="1" colspan="1">297 (84.1)</td><td rowspan="1" colspan="1">49 (87.5)</td><td rowspan="1" colspan="1">.654</td></tr><tr><td rowspan="1" colspan="1">Hydroxychloroquine (%)</td><td rowspan="1" colspan="1">287 (81.3)</td><td rowspan="1" colspan="1">47 (83.9)</td><td rowspan="1" colspan="1">.775</td></tr><tr><td rowspan="1" colspan="1">Immunomodulatory therapy (%)<sup><xref rid="table-fn13-11782218231160014" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">126 (35.7)</td><td rowspan="1" colspan="1">14 (25.0)</td><td rowspan="1" colspan="1">.157</td></tr><tr><td rowspan="1" colspan="1">&#8195;Anakinra (%)</td><td rowspan="1" colspan="1">23 (6.5)</td><td rowspan="1" colspan="1">7 (12.5)</td><td rowspan="1" colspan="1">.187</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sarilumab (%)</td><td rowspan="1" colspan="1">25 (7.1)</td><td rowspan="1" colspan="1">2 (3.6)</td><td rowspan="1" colspan="1">.560</td></tr><tr><td rowspan="1" colspan="1">&#8195;Tocilizumab (%)</td><td rowspan="1" colspan="1">82 (23.2)</td><td rowspan="1" colspan="1">6 (10.7)</td><td rowspan="1" colspan="1">.052</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Clinical complications</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Any complications (%)</td><td rowspan="1" colspan="1">162 (45.9)</td><td rowspan="1" colspan="1">23 (41.8)</td><td rowspan="1" colspan="1">.675</td></tr><tr><td rowspan="1" colspan="1">Bacterial pneumonia (%)</td><td rowspan="1" colspan="1">152 (43.1)</td><td rowspan="1" colspan="1">20 (35.7)</td><td rowspan="1" colspan="1">.374</td></tr><tr><td rowspan="1" colspan="1">Bacteremia (%)</td><td rowspan="1" colspan="1">13 (3.7)</td><td rowspan="1" colspan="1">4 (7.1)</td><td rowspan="1" colspan="1">.269</td></tr><tr><td rowspan="1" colspan="1">Wound infection (%)</td><td rowspan="1" colspan="1">2 (0.6)</td><td rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1">.358</td></tr><tr><td rowspan="1" colspan="1">Venous thromboembolism (%)</td><td rowspan="1" colspan="1">5 (1.4)</td><td rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1">.583</td></tr><tr><td rowspan="1" colspan="1">Stroke (%)</td><td rowspan="1" colspan="1">1 (0.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Renal failure requiring dialysis (%)</td><td rowspan="1" colspan="1">11 (3.1)</td><td rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Acute hepatocellular hepatitis (%)</td><td rowspan="1" colspan="1">5 (1.4)</td><td rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1">.583</td></tr><tr><td rowspan="1" colspan="1">STEMI/NSTEMI<sup><xref rid="table-fn14-11782218231160014" ref-type="table-fn">b</xref></sup>
(%)</td><td rowspan="1" colspan="1">9 (2.5)</td><td rowspan="1" colspan="1">3 (5.4)</td><td rowspan="1" colspan="1">.218</td></tr><tr><td rowspan="1" colspan="1">Multisystem organ failure (%)</td><td rowspan="1" colspan="1">14 (4.0)</td><td rowspan="1" colspan="1">2 (3.6)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Resource Utilization</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Hospital length of stay, days (mean (sd))</td><td rowspan="1" colspan="1">7.00 (7.0)</td><td rowspan="1" colspan="1">8.00 (8.0)</td><td rowspan="1" colspan="1">.123</td></tr><tr><td rowspan="1" colspan="1">ICU<sup><xref rid="table-fn15-11782218231160014" ref-type="table-fn">c</xref></sup>
admission (%)</td><td rowspan="1" colspan="1">93 (26.3)</td><td rowspan="1" colspan="1">16 (28.6)</td><td rowspan="1" colspan="1">.851</td></tr><tr><td rowspan="1" colspan="1">ICU length of stay, days (mean (sd); n&#8201;=&#8201;109)</td><td rowspan="1" colspan="1">7.00 (11.0)</td><td rowspan="1" colspan="1">8.50 (11.8)</td><td rowspan="1" colspan="1">.877</td></tr><tr><td rowspan="1" colspan="1">Days from hospitalization to ICU (n&#8201;=&#8201;109)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.400</td></tr><tr><td rowspan="1" colspan="1">&#8195;0 (%)</td><td rowspan="1" colspan="1">40 (43.0)</td><td rowspan="1" colspan="1">10 (62.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;1-5 (%)</td><td rowspan="1" colspan="1">47 (50.5)</td><td rowspan="1" colspan="1">5 (31.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;6-10 (%)</td><td rowspan="1" colspan="1">4 (4.3)</td><td rowspan="1" colspan="1">1 (6.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&gt;10 (%)</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mechanical ventilation (%)</td><td rowspan="1" colspan="1">63 (17.8)</td><td rowspan="1" colspan="1">12 (21.4)</td><td rowspan="1" colspan="1">.647</td></tr><tr><td rowspan="1" colspan="1">Days from hospitalization to intubation (n&#8201;=&#8201;75)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.113</td></tr><tr><td rowspan="1" colspan="1">&#8195;0 (%)</td><td rowspan="1" colspan="1">15 (23.8)</td><td rowspan="1" colspan="1">6 (50.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;1-5 (%)</td><td rowspan="1" colspan="1">35 (55.6)</td><td rowspan="1" colspan="1">5 (41.7)</td><td rowspan="1" colspan="1">&#8195;6-10 (%)</td></tr><tr><td rowspan="1" colspan="1">11 (17.5)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">&#8195;&gt;10 (%)</td><td rowspan="1" colspan="1">2 (3.2)</td></tr><tr><td rowspan="1" colspan="1">1 (8.3)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn12-11782218231160014"><label>*</label><p>Chi-squared tests for categorical variables, Fisher&#8217;s exact test for
categorical variables with small cell counts, t-tests for continuous
variables, and Wilcoxon rank-sum test for non-normal continuous
variables.</p></fn><fn id="table-fn13-11782218231160014"><label>a</label><p>Some patients received more than one immunomodulatory agent.</p></fn><fn id="table-fn14-11782218231160014"><label>b</label><p>STEMI&#8201;=&#8201;ST segment elevation myocardial infarction and
NSTEMI&#8201;=&#8201;non-ST segment elevation myocardial infarction.</p></fn><fn id="table-fn15-11782218231160014"><label>c</label><p>Intensive care unit.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table4-11782218231160014" orientation="portrait"><label>Table 4.</label><caption><p>Multivariable logistic regression for the outcome of death.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-table4.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Risk factor</th><th align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">Adjusted <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Substance use disorder</td><td rowspan="1" colspan="1">1.03 (0.31, 3.10)</td><td rowspan="1" colspan="1">.964</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">1.91 (0.78, 5.04)</td><td rowspan="1" colspan="1">.170</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.04 (1.01, 1.08)</td><td rowspan="1" colspan="1">.021</td></tr><tr><td rowspan="1" colspan="1">Non-White race</td><td rowspan="1" colspan="1">0.57 (0.21, 1.63)</td><td rowspan="1" colspan="1">.273</td></tr><tr><td rowspan="1" colspan="1">SpO<sub>2</sub>/FiO<sub>2</sub><sup><xref rid="table-fn16-11782218231160014" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">0.58 (0.41, 0.84)</td><td rowspan="1" colspan="1">.003</td></tr><tr><td rowspan="1" colspan="1">IL-6 Receptor inhibitor<sup><xref rid="table-fn17-11782218231160014" ref-type="table-fn">b</xref></sup>
therapy</td><td rowspan="1" colspan="1">1.92 (0.76, 4.81)</td><td rowspan="1" colspan="1">.160</td></tr><tr><td rowspan="1" colspan="1">Cardiac disease<sup><xref rid="table-fn18-11782218231160014" ref-type="table-fn">c</xref></sup></td><td rowspan="1" colspan="1">2.55 (1.00, 6.54)</td><td rowspan="1" colspan="1">.049</td></tr><tr><td rowspan="1" colspan="1">Tobacco use</td><td rowspan="1" colspan="1">2.31 (0.93, 5.84)</td><td rowspan="1" colspan="1">.071</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn16-11782218231160014"><label>a</label><p>Ratio of peripheral capillary oxygen saturation to fraction of
inspired oxygen, to measure oxygenation on hospital admission in
units of 1 standard deviation.</p></fn><fn id="table-fn17-11782218231160014"><label>b</label><p>Interleukin-6 inhibitor: use of tocilizumab or sarilumab as COVID-19
directed therapy per hospital protocol.</p></fn><fn id="table-fn18-11782218231160014"><label>c</label><p>Coronary artery disease, congenital heart disease, or heart
failure.</p></fn></table-wrap-foot></table-wrap><p>We did not find any associations between SUD and clinical secondary outcomes in
the bivariate analysis, including the composite index of &#8220;any complications&#8221;
(<xref rid="table3-11782218231160014" ref-type="table">Table 3</xref>).
Resource utilization secondary outcomes were also similar in the bivariate
analysis (<xref rid="table3-11782218231160014" ref-type="table">Table
3</xref>).</p><p>COVID-19 directed therapies were similar between groups in the bivariate model,
although there was a trend toward increased treatment with tocilizumab in the
non-SUD group (<italic toggle="yes">P</italic>&#8201;=&#8201;.052; <xref rid="table3-11782218231160014" ref-type="table">Table 3</xref>). We then evaluated factors
associated with receiving an IL-6 receptor inhibitor (tocilizumab or sarilumab)
for COVID-19 directed treatment per the BMC hospital protocol, using
multivariable regression adjusting for age, sex, non-White race, baseline
oxygenation by SpO<sub>2</sub>/FiO<sub>2</sub>, obesity, mechanical ventilation,
fever, tobacco use, and hospital length of stay. In this model, there was no
association between SUD and treatment with an IL-6 receptor inhibitor (aOR 0.45;
0.17-1.09; <xref rid="table5-11782218231160014" ref-type="table">Table
5</xref>). Factors significantly associated with treatment with an IL-6 receptor
inhibitor included male sex (aOR 1.78; 1.02-3.15), non-White race (aOR 2.71;
1.16-7.13), obesity (aOR 2.26; 1.26-4.13), fever (aOR 3.82; 1.87-8.50), tobacco
use (aOR 0.51; 0.26-0.97), and hospital length of stay (aOR 1.06;
1.02-1.10).</p><table-wrap position="float" id="table5-11782218231160014" orientation="portrait"><label>Table 5.</label><caption><p>Multivariable logistic regression for the outcome of treatment with IL-6
receptor inhibitor.<sup><xref rid="table-fn19-11782218231160014" ref-type="table-fn">a</xref></sup></p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_11782218231160014-table5.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Risk factor</th><th align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">Adjusted <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Substance use disorder</td><td rowspan="1" colspan="1">0.45 (0.17, 1.09)</td><td rowspan="1" colspan="1">.091</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.01 (0.99, 1.03)</td><td rowspan="1" colspan="1">.473</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">1.78 (1.02, 3.15)</td><td rowspan="1" colspan="1">.044</td></tr><tr><td rowspan="1" colspan="1">Non-White race</td><td rowspan="1" colspan="1">2.71 (1.16, 7.13)</td><td rowspan="1" colspan="1">.030</td></tr><tr><td rowspan="1" colspan="1">SpO<sub>2</sub>/FiO<sub>2</sub><sup><xref rid="table-fn20-11782218231160014" ref-type="table-fn">b</xref></sup></td><td rowspan="1" colspan="1">0.75 (0.56, 1.02)</td><td rowspan="1" colspan="1">.060</td></tr><tr><td rowspan="1" colspan="1">Obesity<sup><xref rid="table-fn21-11782218231160014" ref-type="table-fn">c</xref></sup></td><td rowspan="1" colspan="1">2.26 (1.26, 4.13)</td><td rowspan="1" colspan="1">.007</td></tr><tr><td rowspan="1" colspan="1">Mechanical ventilation</td><td rowspan="1" colspan="1">1.85 (0.87, 3.97)</td><td rowspan="1" colspan="1">.111</td></tr><tr><td rowspan="1" colspan="1">Fever</td><td rowspan="1" colspan="1">3.82 (1.87, 8.50)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">Tobacco use</td><td rowspan="1" colspan="1">0.51 (0.26, 0.97)</td><td rowspan="1" colspan="1">.045</td></tr><tr><td rowspan="1" colspan="1">Length of hospital stay</td><td rowspan="1" colspan="1">1.06 (1.02, 1.10)</td><td rowspan="1" colspan="1">.003</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn19-11782218231160014"><label>a</label><p>Interleukin-6 receptor inhibitor: use of tocilizumab or sarilumab as
COVID-19 directed therapy per hospital protocol.</p></fn><fn id="table-fn20-11782218231160014"><label>b</label><p>Ratio of peripheral capillary oxygen saturation to fraction of
inspired oxygen, to measure oxygenation on hospital admission in
units of 1 standard deviation.</p></fn><fn id="table-fn21-11782218231160014"><label>c</label><p>Body mass index &#10878;30&#8201;kg/m&#178;.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section15-11782218231160014"><title>Discussion</title><p>In this retrospective cohort study of patients admitted to a safety net hospital
during the early phase of the COVID-19 pandemic, SUD was not associated with the
primary outcome of COVID-19-associated inpatient mortality. The secondary analysis
showed that those with and without SUD had similar COVID-19-related clinical
complications, including secondary infections, renal failure requiring dialysis,
acute liver injury, venous thromboembolism, cardiac complications, and the composite
&#8220;any complications.&#8221; Of note, some clinical outcomes such as stroke were very
uncommon overall. Likewise, there was no difference in resource utilization
secondary outcomes between the 2 groups. In contrast to other studies,<sup><xref rid="bibr7-11782218231160014" ref-type="bibr">7</xref>,<xref rid="bibr10-11782218231160014" ref-type="bibr">10</xref></sup> we found similar likelihood
of mechanical ventilation and ICU admission in patients with and without SUD.
Although patients with SUD presented to the hospital earlier in their disease
course, their total hospital length of stay was ultimately similar to patients
without SUD. Insights such as these into the clinical complications and resource
utilization patterns of patients with SUD and COVID-19 can help clinicians
anticipate the trajectory of infection and healthcare needs in this vulnerable
group.</p><p>As BMC sees a high proportion of patients who use substances, it was an apt location
for the study: almost 14% of the study population had SUD, exceeding the national
average of 10.8% in people ages 18 or older.<sup><xref rid="bibr31-11782218231160014" ref-type="bibr">31</xref></sup> We also present findings on
complications from COVID-19 in people with SUD beyond hospitalization, intubation,
and death. The observed similarity in complication rates is particularly important
given BMC&#8217;s diverse patient population that is largely composed of groups
disproportionately impacted by COVID-19, namely Black and Latino
populations.<sup><xref rid="bibr32-11782218231160014" ref-type="bibr">32</xref></sup> This study also evaluated for duration of symptoms before
hospital presentation, which is not often included as a variable in observational
studies of COVID-19 despite the importance of early treatment for severe
disease.<sup><xref rid="bibr28-11782218231160014" ref-type="bibr">28</xref>,<xref rid="bibr33-11782218231160014" ref-type="bibr">33</xref></sup> The timing early in the pandemic provides a more complete
picture of the natural history of the interaction of substance use and COVID-19, as
many now-standard inpatient therapies like corticosteroids and monoclonal antibodies
were not yet part of routine care.<sup><xref rid="bibr29-11782218231160014" ref-type="bibr">29</xref></sup></p><p>The similarity in complications between those with and without SUD run counter to
some published works that have shown worse outcomes in those with SUD<sup><xref rid="bibr7-11782218231160014" ref-type="bibr">7</xref><xref rid="bibr8-11782218231160014" ref-type="bibr"/><xref rid="bibr9-11782218231160014" ref-type="bibr"/>-<xref rid="bibr10-11782218231160014" ref-type="bibr">10</xref></sup> and led to the classification
of those with SUD as &#8220;suggestive higher risk for severe COVID-19 outcomes&#8221; by the
Centers for Disease Control and Prevention.<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup> Some hypotheses have been
proposed to explain worse outcomes seen in other cohorts of people with SUD. One
United States-based study found higher rates of cardiovascular, renal, liver, and
pulmonary disease in patients with SUD, which may in part explain the higher rates
of morbidity and mortality.<sup><xref rid="bibr8-11782218231160014" ref-type="bibr">8</xref></sup> In line with these findings and other known COVID-19 risk
factors,<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup> underlying cardiac disease, increased age, and lower
oxygenation on admission were associated with mortality in our cohort. Similarly, a
database review of approximately 5550 people with COVID-19 showed increased rates of
hospitalization, intubation, and mortality in those with a SUD diagnosis but also
noted that the increased mortality in this group was attenuated after controlling
for hypertension, chronic obstructive pulmonary disease, ischemic heart disease, and
cerebrovascular disease.<sup><xref rid="bibr7-11782218231160014" ref-type="bibr">7</xref></sup> In our cohort those with SUD had baseline higher rates of
pulmonary disease but similar rates of other comorbidities known to contribute to
COVID-19 mortality, such as obesity, diabetes, and cardiovascular disease.<sup><xref rid="bibr34-11782218231160014" ref-type="bibr">34</xref>,<xref rid="bibr35-11782218231160014" ref-type="bibr">35</xref></sup> However,
chronic pulmonary disease was not significantly associated with mortality in our
cohort and therefore were not included as a covariate in the final model. As our
cohort had otherwise similar baseline comorbid conditions and similar outcomes in
those with and without SUD, the previously reported increased COVID-19 complications
in patients with SUD may in fact be secondary to increased rates of underlying
medical conditions in this population.</p><p>We considered that our outcomes may have differed from those in other studies because
of BMC&#8217;s regular use of IL-6 receptor inhibitors as COVID-19-directed therapy, which
was uncommon early in the pandemic but is now recommended for severe progressive
COVID-19.<sup><xref rid="bibr29-11782218231160014" ref-type="bibr">29</xref></sup> Thus we conducted a secondary analysis of factors associated
with receipt of IL-6 receptor inhibitors. We found that having SUD was not
associated with increased administration of IL-6 receptor inhibitors, suggesting
that the similar outcomes in those with and without SUD were not strongly impacted
by use of this therapy. Although IL-6 receptor inhibitor therapy may be most
effective when given to severely but not critically ill patients with
COVID-19,<sup><xref rid="bibr28-11782218231160014" ref-type="bibr">28</xref>,<xref rid="bibr29-11782218231160014" ref-type="bibr">29</xref></sup> the SUD group&#8217;s earlier hospital presentation after symptom
onset did not affect odds of IL-6 receptor inhibitor administration or of
mortality.</p><p>Another important factor to note is that as a safety net hospital, Boston Medical
Center has an established program to assess the social needs of patients and to link
individuals with appropriate resources within the medical center and throughout the
community.<sup><xref rid="bibr36-11782218231160014" ref-type="bibr">36</xref></sup> There are also specific programs targeting individuals with
SUD. These programs might explain some of the findings from the current study which
shows that patients with SUD had similar outcomes when compared to individuals
without SUD. The important role of social determinants of health has been
demonstrated in the literature. Studies have shown that social determinants of
health, such as education, employment, income, social support, and community safety,
influence 47% of health outcomes while health behaviors, clinical care, and physical
environment are estimated to account for 34%, 16%, and 3%, respectively.<sup><xref rid="bibr37-11782218231160014" ref-type="bibr">37</xref></sup></p><p>There are some notable limitations to our study. We are presenting results from a
single site, which might limit generalizability of our findings despite the racial
and ethnic diversity of the BMC patient population. Second, the data presented are
from the earliest phase of COVID-19 in the United States, so trends may have
differed with subsequent waves and as COVID-19 management strategies have evolved
over time. Because of this timing, however, we were able to evaluate more granular
clinical outcomes within the same time period of the studies used to determine
COVID-19 risk categories.<sup><xref rid="bibr14-11782218231160014" ref-type="bibr">14</xref></sup> Third, we did not specifically control for socioeconomic
factors like medical insurance status or income level, as over 75% of the BMC
patient population has public payer insurance (Medicare, Medicaid, or Children&#8217;s
Health Insurance Program) or no insurance.<sup><xref rid="bibr17-11782218231160014" ref-type="bibr">17</xref>,<xref rid="bibr37-11782218231160014" ref-type="bibr">37</xref></sup> Lastly, we were not powered
to detect differences in COVID-19 outcomes between current versus past SUD. This
area would benefit from further research.</p><p>In conclusion, in this study of hospitalized individuals at an urban safety net
hospital with a diverse patient population in the early days of the COVID-19
pandemic, inpatient mortality and morbidity between patients with and without SUD
were similar. Our findings provide a detailed evaluation of outcomes in a unique
patient population that has been disproportionately impacted by COVID-19 and may
provide beneficial insights for similar settings across the country. These results
point away from SUD as an independent risk factor for severe COVID-19 and further
suggests a focus on medical comorbidities to mitigate the effects of COVID-19.
Additional studies are needed to further evaluate for differential outcomes in this
high-risk population, particularly in an era of newer COVID-19-directed
therapies.</p></sec><sec sec-type="supplementary-material" id="section16-11782218231160014" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-11782218231160014" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-sat-10.1177_11782218231160014 &#8211; Supplemental material for
Comparing COVID-19-related Morbidity and Mortality Between Patients With and
Without Substance Use Disorders: A Retrospective Cohort Study</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-sat-10.1177_11782218231160014.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-1-sat-10.1177_11782218231160014 for Comparing
COVID-19-related Morbidity and Mortality Between Patients With and Without
Substance Use Disorders: A Retrospective Cohort Study by Angela McLaughlin,
Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay
Sinha and Sabrina A Assoumou in Substance Abuse: Research and Treatment</p></supplementary-material></sec></body><back><ack><p>The authors acknowledge the contributions of Megan Davis, Janhavee Deshpande, Kelly
Drozdowicz, Lauren Dzera, Nirupa Gadi, Annie Heyman, David Leeds, Nivedita Mandal,
Kelvin Noronha, Aneesha Pydi, Alina Razak, Tyler Ryan, Faizah Shareef, Erin Smith,
Preetha Velu, Judy Wang, and Sarah Zambrano for participating in chart review and
data abstraction.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the National Institute on Drug Abuse under grant number K23DA044085
to S.A.A. and R25DA033211 to L.H.; the BU-CHART Fellowship, National Institute
of Allergy and Infectious Disease under grant number T32AI052074) to A.M., L.H.,
and P.S.; the Boston University School of Medicine Department of Medicine Evans
Career Investment and Evans Junior Faculty Merit Awards to S.A.A.; the Burroughs
Wellcome/ASTMH Postdoctoral fellowship to P.S.</p></fn><fn fn-type="COI-statement"><p>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn><fn fn-type="con"><p><bold>Author Contributions:</bold> Conceptualization: AML, RB, SAA. Methodology: MR, AML, RB, SAA. Interpretation of
study data: AML, RB, SAA, PS, LH, WA. Formal analysis: MR, JH. Funding
acquisition: SAA. Supervision: SAA. Writing &#8211; original draft: AML, RB. All
authors were involved in review &amp; editing and had final approval of the
submitted manuscript.</p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-11782218231160014"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahern</surname><given-names>J</given-names></name><name name-style="western"><surname>Stuber</surname><given-names>J</given-names></name><name name-style="western"><surname>Galea</surname><given-names>S.</given-names></name></person-group><article-title>Stigma, discrimination and the health of illicit drug
users</article-title>. <source>Drug Alcohol Depend</source>.
<year>2007</year>;<volume>88</volume>:<fpage>188</fpage>-<lpage>196</lpage>.<pub-id pub-id-type="pmid">17118578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2006.10.014</pub-id></mixed-citation></ref><ref id="bibr2-11782218231160014"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farhoudian</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldacchino</surname><given-names>A</given-names></name><name name-style="western"><surname>Clark</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>COVID-19 and substance use
disorders: Recommendations to a comprehensive healthcare response. An
International Society of Addiction Medicine Practice and Policy Interest
Group Position Paper</article-title>. <source>Basic Clin Neurosci</source>.
<year>2020</year>;<volume>11</volume>:<fpage>133</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">32855772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.32598/bcn.11.covid19.1</pub-id><pub-id pub-id-type="pmcid">PMC7368103</pub-id></mixed-citation></ref><ref id="bibr3-11782218231160014"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palepu</surname><given-names>A</given-names></name><name name-style="western"><surname>Gadermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Hubley</surname><given-names>AM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Substance use and access to
health care and addiction treatment among homeless and vulnerably housed
persons in three Canadian cities</article-title>. <source>PLoS One</source>.
<year>2013</year>;<volume>8</volume>:e75133.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0075133</pub-id><pub-id pub-id-type="pmcid">PMC3790780</pub-id><pub-id pub-id-type="pmid">24124470</pub-id></mixed-citation></ref><ref id="bibr4-11782218231160014"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balaram</surname><given-names>K</given-names></name><name name-style="western"><surname>Marwaha</surname><given-names>R</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>DC.</given-names></name></person-group><article-title>The effects of substance use on severe acute respiratory syndrome
coronavirus infection risks and outcomes</article-title>. <source>Curr Opin
Psychiatry</source>.
<year>2021</year>;<volume>34</volume>:<fpage>386</fpage>-<lpage>392</lpage>.<pub-id pub-id-type="pmid">34001701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/YCO.0000000000000711</pub-id><pub-id pub-id-type="pmcid">PMC8183241</pub-id></mixed-citation></ref><ref id="bibr5-11782218231160014"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haley</surname><given-names>DF</given-names></name><name name-style="western"><surname>Saitz</surname><given-names>R.</given-names></name></person-group><article-title>The opioid epidemic during the COVID-19 pandemic</article-title>.
<source>JAMA</source>.
<year>2020</year>;<volume>324</volume>:<fpage>1615</fpage>-<lpage>1617</lpage>.<pub-id pub-id-type="pmid">32945831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.18543</pub-id></mixed-citation></ref><ref id="bibr6-11782218231160014"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JU</given-names></name><name name-style="western"><surname>Majid</surname><given-names>A</given-names></name><name name-style="western"><surname>Judge</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of COVID-19 lockdown
on alcohol consumption in patients with pre-existing alcohol use
disorder</article-title>. <source>Lancet Gastroenterol Hepatol</source>.
<year>2020</year>;<volume>5</volume>:<fpage>886</fpage>-<lpage>887</lpage>.<pub-id pub-id-type="pmid">32763197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(20)30251-X</pub-id><pub-id pub-id-type="pmcid">PMC7403133</pub-id></mixed-citation></ref><ref id="bibr7-11782218231160014"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baillargeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Polychronopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YF</given-names></name><name name-style="western"><surname>Raji</surname><given-names>MA.</given-names></name></person-group><article-title>The impact of substance use disorder on COVID-19
outcomes</article-title>. <source>Psychiatr Serv</source>.
<year>2021</year>;<volume>72</volume>:<fpage>578</fpage>-<lpage>581</lpage>.<pub-id pub-id-type="pmid">33138712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.202000534</pub-id><pub-id pub-id-type="pmcid">PMC8089118</pub-id></mixed-citation></ref><ref id="bibr8-11782218231160014"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>DC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND.</given-names></name></person-group><article-title>Correction: COVID-19 risk and outcomes in patients with substance
use disorders: analyses from electronic health records in the United
States</article-title>. <source>Mol Psychiatry</source>.
<year>2021</year>;<volume>26</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">32999436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-020-00895-0</pub-id><pub-id pub-id-type="pmcid">PMC7526074</pub-id></mixed-citation></ref><ref id="bibr9-11782218231160014"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilev</surname><given-names>M</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>KB</given-names></name><name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Characteristics and
predictors of hospitalization and death in the first 11 122 cases with a
positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide
cohort</article-title>. <source>Int J Epidemiol</source>.
<year>2020</year>;<volume>49</volume>:
<fpage>1468</fpage>-<lpage>1481</lpage>.<pub-id pub-id-type="pmid">32887982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyaa140</pub-id><pub-id pub-id-type="pmcid">PMC7499657</pub-id></mixed-citation></ref><ref id="bibr10-11782218231160014"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qeadan</surname><given-names>F</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>B</given-names></name><name name-style="western"><surname>Bern</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Opioid use disorder and
health service utilization among COVID-19 patients in the US: a nationwide
cohort from the Cerner Real-World Data</article-title>.
<source>EClinicalMedicine</source>.
<year>2021</year>;<volume>37</volume>:<fpage>100938</fpage>.<pub-id pub-id-type="pmid">34109308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.100938</pub-id><pub-id pub-id-type="pmcid">PMC8177438</pub-id></mixed-citation></ref><ref id="bibr11-11782218231160014"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasin</surname><given-names>DS</given-names></name><name name-style="western"><surname>Fink</surname><given-names>DS</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Substance use disorders and
COVID-19: an analysis of nation-wide Veterans Health Administration
electronic health records</article-title>. <source>Drug Alcohol
Depend</source>.
<year>2022</year>;<volume>234</volume>:<fpage>109383</fpage>.<pub-id pub-id-type="pmid">35279457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2022.109383</pub-id><pub-id pub-id-type="pmcid">PMC8891118</pub-id></mixed-citation></ref><ref id="bibr12-11782218231160014"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bravata</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bent</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Association of Social and
behavioral risk factors with mortality among US veterans with
COVID-19</article-title>. <source>JAMA Netw Open</source>.
<year>2021</year>;<volume>4</volume>:e2113031.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.13031</pub-id><pub-id pub-id-type="pmcid">PMC8190626</pub-id><pub-id pub-id-type="pmid">34106264</pub-id></mixed-citation></ref><ref id="bibr13-11782218231160014"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>B</given-names></name><name name-style="western"><surname>El Shahawy</surname><given-names>O</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hochman</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MR</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>N.</given-names></name></person-group><article-title>Association of substance use disorders and drug overdose with
adverse COVID-19 outcomes in New York City: January-October
2020</article-title>. <source>J Public Health</source>.
<year>2021</year>;<volume>43</volume>:
<fpage>462</fpage>-<lpage>465</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pubmed/fdaa241</pub-id><pub-id pub-id-type="pmcid">PMC7799011</pub-id><pub-id pub-id-type="pmid">33367823</pub-id></mixed-citation></ref><ref id="bibr14-11782218231160014"><label>14</label><mixed-citation publication-type="gov"><collab>Centers for Disease Control and Prevention</collab>.
<article-title>Underlying medical conditions associated with higher risk for
severe COVID-19: Information for healthcare providers</article-title>.
<year>2022</year>. <comment>Accessed March 21, 2022</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</ext-link>.<pub-id pub-id-type="pmid">34009770</pub-id></mixed-citation></ref><ref id="bibr15-11782218231160014"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>CL</given-names></name><name name-style="western"><surname>Santos</surname><given-names>GM</given-names></name><name name-style="western"><surname>Kornbluh</surname><given-names>W</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>S</given-names></name><name name-style="western"><surname>Faul</surname><given-names>M</given-names></name><name name-style="western"><surname>Coffin</surname><given-names>PO.</given-names></name></person-group><article-title>Using ICD-10-CM codes to detect illicit substance use: A
comparison with retrospective self-report</article-title>. <source>Drug
Alcohol Depend</source>.
<year>2021</year>;<volume>221</volume>:<fpage>108537</fpage>.<pub-id pub-id-type="pmid">33621806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108537</pub-id><pub-id pub-id-type="pmcid">PMC11008535</pub-id></mixed-citation></ref><ref id="bibr16-11782218231160014"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EG</given-names></name><name name-style="western"><surname>Stano</surname><given-names>CM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Validation of key
behaviourally based mental health diagnoses in administrative data: suicide
attempt, alcohol abuse, illicit drug abuse and tobacco use</article-title>.
<source>BMC Health Serv Res</source>.
<year>2012</year>;<volume>12</volume>:<fpage>18</fpage>.<pub-id pub-id-type="pmid">22270080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1472-6963-12-18</pub-id><pub-id pub-id-type="pmcid">PMC3280157</pub-id></mixed-citation></ref><ref id="bibr17-11782218231160014"><label>17</label><mixed-citation publication-type="webpage"><collab>Boston Medical Center</collab>. <article-title>About us</article-title>.
2022. <comment>Accessed March 2, 2022</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bmc.org/about-us" ext-link-type="uri">https://www.bmc.org/about-us</ext-link></mixed-citation></ref><ref id="bibr18-11782218231160014"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>RH</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>CM</given-names></name><name name-style="western"><surname>Marathe</surname><given-names>JG</given-names></name></person-group>, <etal>et al</etal>. <article-title>Partnering with state health
departments to address injection-related infections during the opioid
epidemic: experience at a safety net hospital</article-title>. <source>Open
Forum Infect Dis</source>. <year>2021</year>;<volume>8</volume>:
ofab208.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofab208</pub-id><pub-id pub-id-type="pmcid">PMC8364760</pub-id><pub-id pub-id-type="pmid">34409120</pub-id></mixed-citation></ref><ref id="bibr19-11782218231160014"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assoumou</surname><given-names>SA</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Horsburgh</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Drainoni</surname><given-names>ML</given-names></name><name name-style="western"><surname>Linas</surname><given-names>BP.</given-names></name></person-group><article-title>Relationship between hepatitis C clinical testing site and
linkage to care</article-title>. <source>Open Forum Infect Dis</source>.
<year>2014</year>;<volume>1</volume>:ofu009.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofu009</pub-id><pub-id pub-id-type="pmcid">PMC4324178</pub-id><pub-id pub-id-type="pmid">25734083</pub-id></mixed-citation></ref><ref id="bibr20-11782218231160014"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>HE</given-names></name><name name-style="western"><surname>Ashe</surname><given-names>EM</given-names></name><name name-style="western"><surname>Silverstein</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Race/Ethnicity, underlying
medical conditions, homelessness, and hospitalization status of adult
patients with COVID-19 at an urban Safety-Net Medical Center &#8212; Boston,
Massachusetts, 2020</article-title>. <source>MMWR Morb Mortal Wkly
Rep</source>.
<year>2020</year>;<volume>69</volume>:<fpage>864</fpage>-<lpage>869</lpage>.<pub-id pub-id-type="pmid">32644981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6927a3</pub-id><pub-id pub-id-type="pmcid">PMC7727597</pub-id></mixed-citation></ref><ref id="bibr21-11782218231160014"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></name><name name-style="western"><surname>Shintani</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hagerman</surname><given-names>HE</given-names></name></person-group>, <etal>et al</etal>. <article-title>Derivation and validation of
SpO<sub>2</sub>/FiO<sub>2</sub> ratio to impute for Pao2/Fio2 ratio in
the respiratory component of the Sequential Organ Failure Assessment
score</article-title>. <source>Crit Care Med</source>. <year>2009</year>;
<volume>37</volume>:<fpage>1317</fpage>-<lpage>1321</lpage>.<pub-id pub-id-type="pmid">19242333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e31819cefa9</pub-id><pub-id pub-id-type="pmcid">PMC3776410</pub-id></mixed-citation></ref><ref id="bibr22-11782218231160014"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>International study of the
prevalence and outcomes of infection in intensive care
units</article-title>. <source>JAMA</source>.
<year>2009</year>;<volume>302</volume>:<fpage>2323</fpage>-<lpage>2329</lpage>.<pub-id pub-id-type="pmid">19952319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2009.1754</pub-id></mixed-citation></ref><ref id="bibr23-11782218231160014"><label>23</label><mixed-citation publication-type="gov"><collab>National Institute on Alcohol Abuse and Alcoholism</collab>.
<article-title>Drinking levels defined</article-title>. 2021.
<comment>Accessed June 15, 2021</comment>.&#8201;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking" ext-link-type="uri">https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking</ext-link></mixed-citation></ref><ref id="bibr24-11782218231160014"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapham</surname><given-names>GT</given-names></name><name name-style="western"><surname>Matson</surname><given-names>TE</given-names></name><name name-style="western"><surname>Carrell</surname><given-names>DS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Comparison of medical
cannabis use reported on a confidential survey vs documented in the
electronic health record among primary care patients</article-title>.
<source>JAMA Netw Open</source>.
<year>2022</year>;<volume>5</volume>:e2211677.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.11677</pub-id><pub-id pub-id-type="pmcid">PMC9127557</pub-id><pub-id pub-id-type="pmid">35604691</pub-id></mixed-citation></ref><ref id="bibr25-11782218231160014"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serowik</surname><given-names>KL</given-names></name><name name-style="western"><surname>Yonkers</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gilstad-Hayden</surname><given-names>K</given-names></name><name name-style="western"><surname>Forray</surname><given-names>A</given-names></name><name name-style="western"><surname>Zimbrean</surname><given-names>P</given-names></name><name name-style="western"><surname>Martino</surname><given-names>S.</given-names></name></person-group><article-title>Substance use disorder detection rates among providers of general
medical inpatients</article-title>. <source>J Gen Intern Med</source>.
<year>2021</year>;<volume>36</volume>:<fpage>668</fpage>-<lpage>675</lpage>.<pub-id pub-id-type="pmid">33111239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-020-06319-7</pub-id><pub-id pub-id-type="pmcid">PMC7947066</pub-id></mixed-citation></ref><ref id="bibr26-11782218231160014"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sajdeya</surname><given-names>R</given-names></name><name name-style="western"><surname>Goodin</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Tighe</surname><given-names>PJ.</given-names></name></person-group><article-title>Cannabis use assessment and documentation in healthcare:
Priorities for closing the gap</article-title>. <source>Prev Med</source>.
<year>2021</year>;<volume>153</volume>:<fpage>106798</fpage>.<pub-id pub-id-type="pmid">34506820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2021.106798</pub-id></mixed-citation></ref><ref id="bibr27-11782218231160014"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrell</surname><given-names>DS</given-names></name><name name-style="western"><surname>Cronkite</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Shea</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Clinical documentation of
patient-reported medical cannabis use in primary care: toward scalable
extraction using natural language processing methods</article-title>.
<source>Subst Abuse</source>.
<year>2022</year>;<volume>43</volume>:<fpage>917</fpage>-<lpage>924</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2021.1986767</pub-id><pub-id pub-id-type="pmcid">PMC9134865</pub-id><pub-id pub-id-type="pmid">35254218</pub-id></mixed-citation></ref><ref id="bibr28-11782218231160014"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>P</given-names></name><name name-style="western"><surname>Mostaghim</surname><given-names>A</given-names></name><name name-style="western"><surname>Bielick</surname><given-names>CG</given-names></name></person-group>, <etal>et al</etal>. <article-title>Early administration of
interleukin-6 inhibitors for patients with severe COVID-19 disease is
associated with decreased intubation, reduced mortality, and increased
discharge</article-title>. <source>Int J Infect Dis</source>.
<year>2020</year>;<volume>99</volume>:<fpage>28</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">32721528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.07.023</pub-id><pub-id pub-id-type="pmcid">PMC7591937</pub-id></mixed-citation></ref><ref id="bibr29-11782218231160014"><label>29</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Bhimraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>RL</given-names></name><name name-style="western"><surname>Shumaker</surname><given-names>AH</given-names></name></person-group>, <etal>et al</etal>. <article-title>Infectious Diseases Society
of America guidelines on the treatment and management of patients with
COVID-19</article-title>. <year>2021</year>. <comment>Accessed June 8,
2022</comment>.&#8201;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/" ext-link-type="uri">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa478</pub-id><pub-id pub-id-type="pmcid">PMC7197612</pub-id><pub-id pub-id-type="pmid">32338708</pub-id></mixed-citation></ref><ref id="bibr30-11782218231160014"><label>30</label><mixed-citation publication-type="other"><collab>R Core Team</collab>. R software v4.0.3. R Foundation for Statistical
Computing, <year>2020</year>.</mixed-citation></ref><ref id="bibr31-11782218231160014"><label>31</label><mixed-citation publication-type="book"><collab>Substance Abuse and Mental Health Services Administration</collab>.
<source>Key Substance Use and Mental Health Indicators in the United States:
Results from the 2018 National Survey on Drug Use and Health (HHS
Publication No. PEP19-5068, NSDUH Series H-54)</source>.
<publisher-name>Center for Behavioral Health Statistics and Quality,
Substance Abuse and Mental Health Services Administration</publisher-name>.
<year>2019</year>. <comment>Accessed March 31, 2022</comment>.&#8201;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/" ext-link-type="uri">https://www.samhsa.gov/data/</ext-link></mixed-citation></ref><ref id="bibr32-11782218231160014"><label>32</label><mixed-citation publication-type="gov"><collab>Centers for Disease Control and Prevention</collab>.
<article-title>COVID-19: Risk for COVID-19 infection, hospitalization, and
death by race/ethnicity</article-title>. 2022. <comment>Accessed March 31,
2022</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html</ext-link></mixed-citation></ref><ref id="bibr33-11782218231160014"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrak</surname><given-names>RM</given-names></name><name name-style="western"><surname>Van Hise</surname><given-names>NW</given-names></name><name name-style="western"><surname>Skorodin</surname><given-names>NC</given-names></name></person-group>, <etal>et al</etal>. <article-title>Early tocilizumab dosing is
associated with improved survival in critically ill patients infected with
severe acute respiratory syndrome coronavirus-2</article-title>.
<source>Crit Care Explor</source>.
<year>2021</year>;<volume>3</volume>:e0395.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCE.0000000000000395</pub-id><pub-id pub-id-type="pmcid">PMC8009634</pub-id><pub-id pub-id-type="pmid">33817660</pub-id></mixed-citation></ref><ref id="bibr34-11782218231160014"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study</article-title>. <source>Lancet</source>.
<year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>-<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmcid">PMC7270627</pub-id></mixed-citation></ref><ref id="bibr35-11782218231160014"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grasselli</surname><given-names>G</given-names></name><name name-style="western"><surname>Zangrillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Zanella</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Baseline characteristics and
outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the
Lombardy region, Italy</article-title>. <source>JAMA</source>.
<year>2020</year>;<volume>323</volume>:<fpage>1574</fpage>-<lpage>1581</lpage>.<pub-id pub-id-type="pmid">32250385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.5394</pub-id><pub-id pub-id-type="pmcid">PMC7136855</pub-id></mixed-citation></ref><ref id="bibr36-11782218231160014"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buitron de la
Vega</surname><given-names>P</given-names></name><name name-style="western"><surname>Losi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sprague Martinez</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Implementing an EHR-based
screening and referral system to address social determinants of health in
primary care</article-title>. <source>Med Care</source>.
<year>2019</year>;<volume>57</volume>:S133-S139.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0000000000001029</pub-id><pub-id pub-id-type="pmid">31095052</pub-id></mixed-citation></ref><ref id="bibr37-11782218231160014"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hood</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gennuso</surname><given-names>KP</given-names></name><name name-style="western"><surname>Swain</surname><given-names>GR</given-names></name><name name-style="western"><surname>Catlin</surname><given-names>BB.</given-names></name></person-group><article-title>County health rankings: relationships between determinant factors
and health outcomes</article-title>. <source>Am J Prev Med</source>.
<year>2016</year>;<volume>50</volume>:<fpage>129</fpage>-<lpage>135</lpage>.<pub-id pub-id-type="pmid">26526164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2015.08.024</pub-id></mixed-citation></ref><ref id="bibr38-11782218231160014"><label>38</label><mixed-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Romulus</surname><given-names>Y</given-names></name></person-group>, on behalf of the Children&#8217;s Health Access Coalition.
<collab>RE: MassHealth Section</collab><article-title>1115 Demonstration Waiver Amendment [press
release]</article-title>. <month>April</month><day>23</day>, <year>2021</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mass.gov/doc/public-comments-to-proposed-masshealth-section-1115-demonstration-waiver-amendment-request-6-8-21/download" ext-link-type="uri">https://www.mass.gov/doc/public-comments-to-proposed-masshealth-section-1115-demonstration-waiver-amendment-request-6-8-21/download</ext-link></mixed-citation></ref></ref-list></back></article></pmc-articleset>